vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and WORLD ACCEPTANCE CORP (WRLD). Click either name above to swap in a different company.

WORLD ACCEPTANCE CORP is the larger business by last-quarter revenue ($141.3M vs $74.7M, roughly 1.9× Health Catalyst, Inc.). WORLD ACCEPTANCE CORP runs the higher net margin — -0.6% vs -121.9%, a 121.2% gap on every dollar of revenue. On growth, WORLD ACCEPTANCE CORP posted the faster year-over-year revenue change (1.9% vs -6.2%). WORLD ACCEPTANCE CORP produced more free cash flow last quarter ($57.2M vs $9.6M). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -5.8%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

Credit Acceptance Corporation is an auto finance company providing automobile loans and other related financial products. The company operates its financial program through a national network of dealer-partners, the automobile dealers participating in the programs. The company operates two programs: the "Portfolio Program" and the "Purchase Program". Through these programs, the company can advance money to automobile dealers in exchange for the right to service the underlying consumer loans a...

HCAT vs WRLD — Head-to-Head

Bigger by revenue
WRLD
WRLD
1.9× larger
WRLD
$141.3M
$74.7M
HCAT
Growing faster (revenue YoY)
WRLD
WRLD
+8.1% gap
WRLD
1.9%
-6.2%
HCAT
Higher net margin
WRLD
WRLD
121.2% more per $
WRLD
-0.6%
-121.9%
HCAT
More free cash flow
WRLD
WRLD
$47.5M more FCF
WRLD
$57.2M
$9.6M
HCAT
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-5.8%
WRLD

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
HCAT
HCAT
WRLD
WRLD
Revenue
$74.7M
$141.3M
Net Profit
$-91.0M
$-911.3K
Gross Margin
Operating Margin
-115.3%
-0.7%
Net Margin
-121.9%
-0.6%
Revenue YoY
-6.2%
1.9%
Net Profit YoY
-340.3%
-106.8%
EPS (diluted)
$-1.29
$-0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
WRLD
WRLD
Q4 25
$74.7M
$141.3M
Q3 25
$76.3M
$134.5M
Q2 25
$80.7M
$132.5M
Q1 25
$79.4M
$165.3M
Q4 24
$79.6M
$138.6M
Q3 24
$76.4M
$131.4M
Q2 24
$75.9M
$129.5M
Q1 24
$74.7M
$159.3M
Net Profit
HCAT
HCAT
WRLD
WRLD
Q4 25
$-91.0M
$-911.3K
Q3 25
$-22.2M
$-1.9M
Q2 25
$-41.0M
$1.3M
Q1 25
$-23.7M
$44.3M
Q4 24
$-20.7M
$13.4M
Q3 24
$-14.7M
$22.1M
Q2 24
$-13.5M
$9.9M
Q1 24
$-20.6M
$35.1M
Gross Margin
HCAT
HCAT
WRLD
WRLD
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
HCAT
HCAT
WRLD
WRLD
Q4 25
-115.3%
-0.7%
Q3 25
-22.9%
-1.3%
Q2 25
-46.0%
1.5%
Q1 25
-25.4%
33.3%
Q4 24
-22.0%
11.6%
Q3 24
-17.9%
21.3%
Q2 24
-20.8%
10.0%
Q1 24
-30.5%
29.3%
Net Margin
HCAT
HCAT
WRLD
WRLD
Q4 25
-121.9%
-0.6%
Q3 25
-29.1%
-1.4%
Q2 25
-50.8%
1.0%
Q1 25
-29.9%
26.8%
Q4 24
-26.0%
9.7%
Q3 24
-19.3%
16.8%
Q2 24
-17.8%
7.7%
Q1 24
-27.6%
22.0%
EPS (diluted)
HCAT
HCAT
WRLD
WRLD
Q4 25
$-1.29
$-0.19
Q3 25
$-0.32
$-0.38
Q2 25
$-0.59
$0.25
Q1 25
$-0.35
$8.07
Q4 24
$-0.33
$2.45
Q3 24
$-0.24
$3.99
Q2 24
$-0.23
$1.79
Q1 24
$-0.35
$6.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
WRLD
WRLD
Cash + ST InvestmentsLiquidity on hand
$95.7M
$10.0M
Total DebtLower is stronger
$153.3M
$677.2M
Stockholders' EquityBook value
$245.8M
$351.6M
Total Assets
$502.6M
$1.1B
Debt / EquityLower = less leverage
0.62×
1.93×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
WRLD
WRLD
Q4 25
$95.7M
$10.0M
Q3 25
$91.5M
$14.9M
Q2 25
$97.3M
$8.1M
Q1 25
$342.0M
$4.7M
Q4 24
$392.0M
$10.3M
Q3 24
$387.3M
$9.7M
Q2 24
$308.3M
$11.1M
Q1 24
$327.8M
$5.2M
Total Debt
HCAT
HCAT
WRLD
WRLD
Q4 25
$153.3M
$677.2M
Q3 25
$153.1M
$584.6M
Q2 25
$153.0M
$472.5M
Q1 25
$382.9M
$447.9M
Q4 24
$382.4M
$561.2M
Q3 24
$345.0M
$506.6M
Q2 24
$494.7M
Q1 24
$498.4M
Stockholders' Equity
HCAT
HCAT
WRLD
WRLD
Q4 25
$245.8M
$351.6M
Q3 25
$331.9M
$365.6M
Q2 25
$347.5M
$427.9M
Q1 25
$376.8M
$439.5M
Q4 24
$365.2M
$428.2M
Q3 24
$355.0M
$417.5M
Q2 24
$357.0M
$422.6M
Q1 24
$357.2M
$424.4M
Total Assets
HCAT
HCAT
WRLD
WRLD
Q4 25
$502.6M
$1.1B
Q3 25
$587.1M
$1.1B
Q2 25
$616.2M
$1.0B
Q1 25
$891.5M
$1.0B
Q4 24
$858.9M
$1.1B
Q3 24
$813.0M
$1.0B
Q2 24
$691.7M
$1.0B
Q1 24
$695.1M
$1.1B
Debt / Equity
HCAT
HCAT
WRLD
WRLD
Q4 25
0.62×
1.93×
Q3 25
0.46×
1.60×
Q2 25
0.44×
1.10×
Q1 25
1.02×
1.02×
Q4 24
1.05×
1.31×
Q3 24
0.97×
1.21×
Q2 24
1.17×
Q1 24
1.17×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
WRLD
WRLD
Operating Cash FlowLast quarter
$9.9M
$58.0M
Free Cash FlowOCF − Capex
$9.6M
$57.2M
FCF MarginFCF / Revenue
12.9%
40.5%
Capex IntensityCapex / Revenue
0.4%
0.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K
$412.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
WRLD
WRLD
Q4 25
$9.9M
$58.0M
Q3 25
$-464.0K
$48.6M
Q2 25
$-9.0M
$58.2M
Q1 25
$280.0K
$254.2M
Q4 24
$-3.5M
$61.1M
Q3 24
$6.2M
$53.8M
Q2 24
$1.6M
$48.4M
Q1 24
$10.3M
$265.8M
Free Cash Flow
HCAT
HCAT
WRLD
WRLD
Q4 25
$9.6M
$57.2M
Q3 25
$-719.0K
$47.7M
Q2 25
$-9.2M
$57.1M
Q1 25
$-390.0K
$250.5M
Q4 24
$-3.9M
$60.4M
Q3 24
$5.5M
$52.7M
Q2 24
$1.3M
$47.3M
Q1 24
$10.1M
$259.9M
FCF Margin
HCAT
HCAT
WRLD
WRLD
Q4 25
12.9%
40.5%
Q3 25
-0.9%
35.5%
Q2 25
-11.4%
43.1%
Q1 25
-0.5%
151.6%
Q4 24
-4.9%
43.6%
Q3 24
7.2%
40.1%
Q2 24
1.7%
36.5%
Q1 24
13.5%
163.2%
Capex Intensity
HCAT
HCAT
WRLD
WRLD
Q4 25
0.4%
0.6%
Q3 25
0.3%
0.7%
Q2 25
0.3%
0.8%
Q1 25
0.8%
2.2%
Q4 24
0.5%
0.5%
Q3 24
0.9%
0.8%
Q2 24
0.4%
0.8%
Q1 24
0.3%
3.7%
Cash Conversion
HCAT
HCAT
WRLD
WRLD
Q4 25
Q3 25
Q2 25
43.27×
Q1 25
5.74×
Q4 24
4.56×
Q3 24
2.43×
Q2 24
4.87×
Q1 24
7.58×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

WRLD
WRLD

Segment breakdown not available.

Related Comparisons